Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter-2 Inhibitors vs Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes
The incidence rate of DKA among SGLT2i and GLP1RA initiators remained low overall. However, SGLT2i use was associated with a 40% increased risk of hospitalization with DKA compared to GLP1RA use among patients with CKD stages 3-4 and T2D. Clinicians should remain vigilant when monitoring patients with CKD and T2D treated with SGLT2i.
Authors
- HELEN TESFAYE
- Panupong Hansrivijit (ORCID: https://orcid.org/0000-0002-5041-4290)
- Julie M. Paik
- Deborah J. Wexler
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- VA Boston Healthcare System (US)
- Massachusetts General Hospital (US)
- Geriatric Research Education and Clinical Center (US)
Publication Details
- Journal
- Kidney360
- Published
- 2026-02-02
- DOI
- https://doi.org/10.34067/kid.0000001144
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00